Kuros Biosciences announces treatment with Fibrin-PTH

Kuros Biosciences has announced a successful milestone in its STRUCTURE trial: a patient with degenerative disc diseases has been treated with Fibrin-PTH for the first time ever. The clinical trial is taking place in the USA, where surgeries had to be postponed for quite some time due to the COVID-19 pandemic. The treatment was carried out by Dr. Richard Todd Allen, chief physician at the University California San Diego.

In the first investigational trial of its kind, a flowable drug-biologic bone graft was delivered through a narrow-gauge delivery system to achieve interbody spine fusion.

“Not only is this the first time a drug-biologic bone graft is being tested for the treatment of Degenerative Disk Disease (DDD) in patients within a clinical trial, but it is also the first time such a technology is being evaluated for both open and minimally invasive surgical technique under clinical trial conditions,” according to the Kuros press release.

Fifty patients will be enrolled in the STRUCTURE trial, where they will be administered Fibrin-PTH to create solid bone between adjoining vertebrae of the spine. The goal of the treatment is to reduce pain and nerve irritation.

“The treatment of the first patient in the STRUCTURE trial is an important milestone for Kuros’s Fibrin-PTH program,” said Kuros CEO Joost de Bruijn. “Fibrin-PTH targets a substantial clinical need and, if successful, addresses a huge commercial opportunity.” He anticipates that patients can be recruited into the study “without further delay”.

Dr. Todd Allen said: “Given the strong pre-clinical data and ease of application of Fibrin-PTH, being particularly suitable for minimally invasive surgeries, I see great potential for this novel drug-biologic combination product.”

Kuros Biosciences develops products for tissue repair and regeneration. It is a spin-off from the University of Zurich (UZH) and the Swiss Federal Institute of Technology in Zurich (ETH).